News
| 2 min read
Researchers highlight how intra-tumoral microbiota shape tumor growth, drug resistance, and treatment response.
| 4 min read
Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 2 min read
ImmunoVec will use a $40.7 million grant to advance its polymeric nanoparticle platform toward a first-in-human trial for autoimmune diseases.
| 3 min read
A new study showed that adding a drug to inhibit the OPA1 protein could reverse resistance to a frontline treatment in patients with AML.
| 2 min read
Mini “miBrains” replicate key brain cell types, enabling personalized disease research and drug testing.
| 4 min read
Positive results for breast cancer, funding for precision therapies for heart disease, strong results for Lilly’s oral GLP-1, and more led the news this week.
| 3 min read
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
| 2 min read
New study identifies fibroblast subtypes as potential universal drug targets in cancer, skin, and inflammatory diseases.
| 3 min read
A team from Stanford and NYU shows how Bacteroides fragilis can activate pain pathways, revealing a new microbial culprit in digestive disease.
| 6 min read
Vaxart aims to revolutionize immunization by replacing injections with easy-to-take tablets.
| 4 min read
Positive results for a radioligand therapy, a billion-dollar deal for a MASH drug, the Nobel Prize for immune system research, and more led the news this week.
